Tara Bunch on LinkedIn: Queer 50 List 2024 | Fast Company | 18 comments (2024)

Inspired by these innovators and leaders across business and tech. Read on about Fast Company’s Queer 50 List!

5

Here's a list of #LGBTQ #female #nonbinary leaders in business and tech to find inspiration from. You're not alone, and you will succeed. Find a mentor to get relevant experience and advice on the long road ahead.

9

I could not be more thrilled at the level of diversity in this panel of 50 Queer Women and Non-Binary Innovators in Business In Tech. They are gathered because of commonality, but the representation of gender fluidity, race, ethnicity, body shape, age, complexion, and role is incredibly satisfying and I could not be more proud to be a part of this community. #business #tech #diversity #genderdiversity

35

📢Our latest issue is now online! 🌟Featuring articles on perceptions of work-life balance & #gender issues, algorithmic #AI in #IRad, bilateral thalamic high-grade astrocytomas, management and outcomes of glioblastoma, and more....https://ow.ly/3e0L50R77W8

1

Did you know that there are currently no reliable quality measures as to how many in the LGBTQ+ community are living with Parkinson’s disease? 🏳️🌈 🧬 To improve treatment and access to care, there need to be more representative efforts to include LGBTQ+ people in Parkinson’s research and population studies. Today for #PrideMonth, learn about how the Parkinson’s Foundation is working to diversify genetic testing for PD: https://lnkd.in/gRh8JpTg

2

Gene&Cell Therapy >> Adcomm votes yes on Leqembi full OK; Merck brings first IRAlawsuit; Special: LGBTQ+ leaders; Best-paying biopharma jobs; andmore: Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readerscan visit their reader profileto add Endpoints Weekly. New to Endpoints?Sign up here. Amid this busy week with ASCO and BIO, you may have noticed a change in how our paywall operates. The gist of it: From now on, non-paying basic subscribers will get a limited amount of free articles each month, after which we’ll ask you to become a premium subscriber to access our stories. For premium subscribers, nothing will change. Your support has been crucial in growing our newsroom and we look forward to bringing moretimely, unique and in-depth coverage.Adcomm votes yes on Leqembi full OK The FDA’s advisory committee for neurology drugs voted unanimously Friday in favor of full approval for Eisai’s Alzheimer’s drug Leqembi, in line with the agency’s review in its own briefing documents signaling a likely nod. But the lead-up to the panel was not without drama, as David Weisman, a paid consultant for Eisai and Biogen, backed out of the adcomm after some raised questions about potential conflicts of interest.Merck brings first IRA lawsuit Merck filed a lawsuit in federal court to try and invalidate the Inflation Reduction Act, taking the lead in the pharma industry’s opposition to the landmark drug pricing law. And judging from what other companies are saying, Merck is almost certain to have allies quickly join its side.Special: LGBTQ+ leaders In Endpoints’ second year featuring biopharma leaders paving the way for LGBTQ+ scientists, patients, entrepreneurs and C-suites, we’ve seen anti-LGBTQ+ bills in the US and a recent onslaught of anti-gay rhetoric in some corners, Kyle LaHucik notes. While painting the portraits of leaders in the community, we also talk to this year’s honorees about how they speak out during these times.Drug hunter for the undruggable In another world, Greg Verdine would still be building boats and tearing apart car engines in his New Jersey front yard. But in this one, he improbably built a career as a Harvard University professor, serial biotech entrepreneur and iconoclast. Andy Dunn documents Verdine’s career-long obsession to drug the undruggable in a colorful profile, the first in a new series we’re calling In the Lab to feature interesting people in the industry.Exclusive GSK Q&A British drug giant GSK is at an inflection point. Endpoints News’ Drew Armstrong sat down with CEO Emma Walmsley in Cambridge, MA, to talk about the company’s strategy over the next several years, how it’ll sell down and spend its remaining stake in Haleon and the importance of vaccines to the company’s future.Best-paying… #lucidquest #genetherapy #celltherapy

Excited to share my latest review article- one of the first to provide insight on considerations for BMT in individuals identifying as transgender. Check it out below!https://lnkd.in/gb-Ba4dG

38

3 Comments

Interesting piece on inclusion of transgender patients in clinical trials. I like this quote: "The solution is to let the participants choose their risk"https://lnkd.in/gbxCVWMi #diversityequityandinclusion

13

"The results from the reader poll revealed similar themes; persistence and resilience came up as qualities to celebrate." This article is an interesting look at what today's women in science think needs to change in order for there to be gender equality in science.https://buff.ly/42vf8J1 #Women #Science #STEM #WomeninScience #Sciencecareers #Growth #Equality #Genderequality #Equalityintheworkplace #Diversity #Change #Embracechange #WomeninSTEM

2

"People of color, LGBTQ+ patients, and those in underserved urban and rural communities are prevented from accessing, trusting in, and receiving optimal clinical care.”A key to health equity: diverse clinical researchAI plays a vital role in driving progress, but those responsible for conducting clinical trials must ensure that the technology is used for good. This technology can create a more equitable future for everyone by overcoming unconscious biases.Read about the progress via MedCity News: https://lnkd.in/ebEkJPZr#AI #ClincialTrials #Inclusivity

44

4 Comments